-
Eur Radiol: Can bone marrow ADC values guide clinical prediction of prognosis in patients with multiple myeloma?
Time of Update: 2021-02-23
, a recent study published in the journal European Radiology examined the relationship between baseline WB DW-MRI parameters (including ADC values) and progress-free lifetime (PFS) and total lifetime (OS) in newly diagnosed MM patients, clarifying the prognostic value of ADC (esoteric dispersion coefficient) as an important quantitative parameter for dispersive weighted MRI for multiple myeloma (MM).
-
Blood: Isolated pulmonary embolism, don't go the usual way!
Time of Update: 2021-02-12
comparative analysis, it was found that there was the same molecular process between different peculiar pulmonary embolisms, and protein markers specific to isolated pulmonary embolisms were also identified.
-
European Medicines Agency (EMA) grants ARU-1801 priority drug eligibility for sickle cell disease (PRIME)
Time of Update: 2021-02-12
about 10 percent of black Americans have a sickle cell disease gene (that is, they have sickle cellular symptoms).
Biopharmaceutical company Aruvant Sciences announced today that the European Medicines Agency (EMA) has granted ARU-1801 priority drug eligibility (PRIME) for the treatment of sickle cell disease.
-
The listing application for Luspatercept, an innovative drug for blood diseases, was reviewed as a priority by CDE
Time of Update: 2021-02-12
"Luspatercept is the first innovative blood disease drug in China to be included in the priority review after submitting data from overseas clinical trials to CDE," said Dr. Cai Xuexuan, Vice President of Global Research and Development and Head of Research and Development in China.
-
Blood: The more cortisol is used, the worse the prognosis for patients with large B-cell lymphoma treated with CAR T cell therapy!
Time of Update: 2021-02-10
Corticosteroids are often used to manage severe toxicity associated with chimic antigen-treated (CAR) T-cell therapy.
assessed a total of 100 patients, 60 of whom (60%) received corticosteroids to control the toxicity associated with CAR T cell therapy.
-
J Clin Oncol: Treatment of persistent MRD-negative conditions of multiple myeloma (POLLUX and CASTOR) with Daremu monoantigen therapy
Time of Update: 2021-02-10
study aims to assess the correlation between persistent MRD-negative and prognosis in patients with multiple myeloma.
more patients in the treatment group that included daremu monoantigen received MRD-negative and persistent MRD-negative, which was associated with longer progressive survival in patients.
-
FDA awards Bcl-2 inhibitor APG-2575 fifth orphan drug title for treatment of fyring lymphoma (FL)
Time of Update: 2021-02-04
Pharmaceuticals ( FDA ) has awarded its new Bcl-2 inhibitor APG-2575 orphan drug ( ODD ) for the treatment of fable lymphoma ( FL ) , the clinical stage biotechnology company announced today .
-
European Commission grants CLR 131 "orphan drug qualification" for treatment of Waldenstrom globulinemia
Time of Update: 2021-02-04
Waldenstrom globulinemia has a unique clinical pathological manifestation, with lymphocytic lymphoma appearing in the patient's bone marrow and IgM monoclonal globulin disease (globulinemia) in the blood.
-
Nat Genet: What's new! The intestinal bacteria and blood type are regulated by the same gene, and enteritis may be related to your blood type
Time of Update: 2021-02-04
recently, a team at the University of Kiel in Germany published an article in the journal Nature Genetics entitled "Genome-wide association study in 8,956 German individuals influence the ABO histo-blood groups on gut microbiome", identifying for the first time that genetics in the human genome affect the composition of gut microbes, and even more magically, genes that regulate blood type also regulate the composition of microbes in the gut.
-
Cell Death Differ: Atypical NF-B signal transducting paths affect the resistance of chronic lymphocytic leukemia
Time of Update: 2021-02-04
Bcl-XL plays an important role in CLL's venetoclax resistance Researchers have found that CD40-induced NF-B signal transducting paths dominate, which also leads to the activation of both classical and non-classical NF-B signal paths.
-
NAT BME: The transient dilution of hydrogel microsphere inactivation coagulation factor in in-body blood purification
Time of Update: 2021-02-02
, the fake haemophilia model avoids the risk of blood clotting in in vitro circulation, but the lack of coagulation factors is restored when blood is re-imported into the body.
-
J Clin Oncol: International Prognosis Index for Burkitt Lymphoma
Time of Update: 2021-02-02
BL-IPI performance in the validation queue of 457 patients, patient characteristics, BL-IPI grouping relative size and prognostic identification are consistent with the development queue, BL-IPI low, medium and high risk groups of 3 years PFS estimated at 96%, 82% and 63%, respectively.
-
The European Medicines Agency (EMA) has begun a review of GBT's sickle cell therapy Oxbryta
Time of Update: 2021-02-02
Ted Love, President and CEO of GBT, said: "Sickle cell disease has a devastating impact on the lives of patients and their families, including serious and life-threatening complications that can lead to organ damage and premature death.
-
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS
Time of Update: 2021-02-01
About 20% of patients with TP53 mutant bone marrow growth abnormal syndrome (MDS) receive complete remission (CR) after treatment with demthylation drugs.
study is an Ib/II study designed to clarify the safety, recommended Phase II dose and efficacy of Eprenetapopt in the treatment of patients with TP53 mutant MDS or acute myeloid leukemia (AML).
-
Lancet Haematol: Tonadamine-boronitezome-desamisong± Elotuzumab to treat high-risk multiple myeloma
Time of Update: 2021-02-01
(71%) of the 52 patients in the RVd group and 37 of the 48 patients in the RVd-Elotuzumab group (77%) had level 3 or more adverse events.
-
J Clin Oncol: Amine restores the sensitivity of myeloid prosthet syndrome to EPI alpha and improves patient prognostication
Time of Update: 2021-02-01
study aims to clarify whether LEN therapy can restore and improve the response of low-risk, non-del (5q) MDS patients, who show anemia and are less likely to be ineffective or benefit from recombined erythymocytopenic therapy, to EPO α.
-
Blood: ICSD activation disorder induces p53 dependent MCL-1 degradation and MYC-driven lymphoma death
Time of Update: 2021-02-01
In order to determine whether Ribi can be used as a therapeutic target for lymphoma, Domostegui and others have established E-Myc lymphoma cells that express the induced shRNA of ribosome protein (RP) L7a or RPL11, an important component of IRBC.
-
Blood potassium on the test sheet is normal, why did the doctor still prescribe potassium supplements?
Time of Update: 2021-02-01
Here, I believe the patient's friends can understand why the blood potassium at about 3.6mmol/l, the test sheet clearly does not have a downward arrow, and the doctor will still give you a prescription potassium supplement.
-
J Clin Oncol: Abatacept co-stimulation blocking is significantly effective in preventing acute GVHD!
Time of Update: 2021-02-01
the study process recruited adults and children with malignant blood disease and divided into two queues: 1) random double-blind placebo-controlled queues (8/8-HLA-matched URD), compared to CNI/MTX-Absap vs.
-
YESCARTA approved in Japan for treatment of relapsed and difficult-to-treat large B-cell lymphoma (DLBCL)
Time of Update: 2021-02-01
Japan's Ministry of Health, Labour and Industry (MHLW) has approved the embedded antigen-subject (CAR) T-cell therapy YESCARTA® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed and difficult-to-treat large B-cell lymphoma (DLBCL), the company announced today.
